(Q38024436)

27 August 2017

title

The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges (English)

1 reference

27 August 2017

1 reference

Mohamed H Ahmed

1

1 reference

27 August 2017

Ayman Al-Atta

series ordinal

2

1 reference

27 August 2017

Mahir A Hamad

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

7 July 2012

1 reference

Expert Opinion on Pharmacotherapy

27 August 2017

published in

1 reference

27 August 2017

volume

13

1 reference

27 August 2017

issue

13

1 reference

27 August 2017

page(s)

1901-1909

1 reference

Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Cardiovascular disease in HIV-infected patients: does HIV infection in and of itself increase cardiovascular risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Factors Associated with the Incidence of Type 2 Diabetes Mellitus in HIV-Infected Participants in the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Statins as potential treatment for cholesterol gallstones: an attempt to understand the underlying mechanism of actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Management of protease inhibitor-associated hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Intervention for hyperlipidemia associated with protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Dyslipidemia and lipid management in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Rosuvastatin as treatment for non alcoholic steatohepatitis (NASH) and highly active antiretroviral therapy (HAART)-dyslipidaemia: new treatment for global dangers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Rosuvastatin for the treatment of dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Preliminary experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Lipid-lowering agents and new onset diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Characterization of a new circulating recombinant form comprising HIV-1 subtypes C and B in southern Brazil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

A retrospective study of the lipid-lowering efficacy and safety of ezetimibe added to hydroxy methylglutaryl coenzyme A reductase therapy in HIV-infected patients with hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Fenofibrate in the treatment of dyslipidemia associated with HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Fatty liver disease is associated with underlying cardiovascular disease in HIV-infected persons(*).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Current treatment of non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706604

10.1517/14656566.2012.706604

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference